18 results
8-K
EX-99.2
RPTX
Repare Therapeutics Inc
7 May 24
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
4:10pm
cellular target engagement IC50 5 nM Cell proliferation DLD1 / HCT116 (BRCA2mt) EC50 4 / 7 nM Selectiv. Off-target ATPase (HELQ, WRN, BLM) IC50 10 µM
8-K
EX-99.1
q8ptosuo4
13 May 21
Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
4:45pm
8-K
EX-99.1
iuf1bgokan33 flpn9
8 Apr 21
Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event
11:10am
DEF 14A
5yb28vcqf8b bxnqn
1 Apr 21
Definitive proxy
7:36am
S-1/A
EX-10.5
kjztcixhxw
15 Jun 20
IPO registration (amended)
6:18am
S-1/A
EX-10.7
dcrgg o8y
15 Jun 20
IPO registration (amended)
6:18am
S-1/A
EX-10.9
wfxcfh6g9c yw1if516
15 Jun 20
IPO registration (amended)
6:18am
S-1/A
EX-10.10
1zkqz
15 Jun 20
IPO registration (amended)
6:18am
S-1/A
EX-10.8
4tqkvbizs9am
15 Jun 20
IPO registration (amended)
6:18am
S-1
EX-10.1
tlsbkw 8md
29 May 20
IPO registration
5:26pm
DRS
EX-10.1
7529a
6 Apr 20
Draft registration statement
12:00am
- Prev
- 1
- Next